NCT00437489View on ClinicalTrials.gov

A Clinical Trial Comparing The Efficacy And Safety Of 2 Different Initial Dose Prescriptions For Exubera.

PHASE4TerminatedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Inhaled Human Insulin (Exubera)

Initial dose (mg) as per weight based formula = 0.05 x body weight (kg) TID

DRUG

Inhaled Human Insulin (Exubera)

Initial dose of 1mg TID of inhaled human insulin

Trial Locations (9)

1102

Pfizer Investigational Site, Quezon City

1218

Pfizer Investigational Site, Makati

1300

Pfizer Investigational Site, Pasay

1605

Pfizer Investigational Site, Pasig

1810

Pfizer Investigational Site, Marikina City

74600

Pfizer Investigational Site, Karachi

119074

Pfizer Investigational Site, Singapore

159964

Pfizer Investigational Site, Singapore

Unknown

Pfizer Investigational Site, Hong Kong

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00437489 - A Clinical Trial Comparing The Efficacy And Safety Of 2 Different Initial Dose Prescriptions For Exubera. | Biotech Hunter | Biotech Hunter